All In Biotech

Drug Trial Radar · NCT01872897

Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients

A Multi-centred, Randomised, Open Label, Placebo-controlled, Two-period Crossover Study to Evaluate 4-hour Esophageal pH Change in GERD Patients After Administration of Compound Sodium Alginate Double Action Chewable Tablets or Matching Placebo Tablets

Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

45

Actual

Start

Jul 2, 2013

Primary completion

Dec 2013

Study completion Dec 2013

Sponsor

Sponsor type
Industry
First posted
Jun 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to assess the effectiveness of the Compound Sodium Alginate Double Action Chewable Tablets compared to placebo on acidic reflux events into the esophagus in patients diagnosed with Gastroesophageal Reflux Disease (GERD).

Conditions

  • Gastroesophageal Reflux Disease

Interventions

  • Sodium Alginate Double Action Chewable TabletsDrug

    4 tablets as a single dose

  • PlaceboDrug

    4 tablets as a single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Time During the 4-hour Post-dosing Period With pH Below pH 4Time frame: 0 to 4 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • RB Investigational Sites

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.